Clarence Machado

Clarence Patrick Machado is the founder of Medivation, Inc. and Medivation LLC (California), both founded in 1995.
Titles held at these companies include Director from 2014 to 2016.
Current jobs include Chairman at Adverum Biotechnologies, Inc. since 2019, Chairman at Prota Therapeutics Pty Ltd., Independent Director at Xenon Pharmaceuticals, Inc. since 2020, Independent Director at Arcus Biosciences, Inc. since 2019, Director at Auransa, Inc., Independent Director at Alumis, Inc. since 2024, and Director at Avenzo Therapeutics, Inc. Former jobs include Chairman at Armaron Bio Ltd., Independent Director at Inotek Pharmaceuticals Corp.
from 2016 to 2018, Independent Director at ACELYRIN, Inc. from 2021 to 2025, Director at Principia Biopharma, Inc. from 2019 to 2020, Independent Director at Turning Point Therapeutics, Inc. from 2019 to 2022, Independent Director at Roivant Sciences Ltd. from 2016 to 2022, Independent Director at Endocyte, Inc. in 2018, Chief Financial Officer, Director & Senior VP at Medivation Neurology LLC from 2003 to 2004, Director at Roivant Sciences, Inc., Director at Sio Gene Therapies, Inc. from 2017 to 2018, Director at Axovant Sciences, Inc. from 2017 to 2018, Independent Director at Montes Archimedes Acquisition Corp., Independent Director at Turnstone Biologics Corp.
from 2018 to 2024, Director at Therachon AG in 2019, Independent Director at Chimerix, Inc. from 2014 to 2024, Independent Director at SCYNEXIS, Inc. from 2015 to 2019, Chief Legal Counsel at Chiron Corp., Chief Financial Officer at Orion Acquisition Corp.
II, Consultant at Cytyc Corp.
in 2002, Principal at Morrison & Foerster LLP, Chief Financial Officer & Senior Vice President at Pro-Duct Health, Inc. from 2000 to 2001, and Member-Supervisory Board at Therachon Holding GmbH.
Education includes an undergraduate degree from Santa Clara University conferred in 1986 and a graduate degree from Harvard Law School conferred in 1989.